Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Acutely Suicidal Patients in the ED
NCT04260607Phase 3Terminated
- Sponsor
- Naval Medical Center Camp Lejeune
- Start
- Jan 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ketamine in suicidal ideation (2 arms), sponsored by Naval Medical Center Camp Lejeune. Primary endpoints: Suicidal Severity - Beck Scale for Suicide Ideation at 1 week and Depression Symptoms - Montgomery-Åsberg Depression Rating Scale Self-report at 1 week. Started Jan 2020; status: terminated.
02
Drugs
ketamine
03
Conditions
suicidal ideation
Beyond the preview
Go deeper on NCT04260607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04260607.